Clinical outcomes and cardiac safety of continuous antiHer2 therapy in c-erbB2-positive metastatic breast cancer patients-Reference-Cited by-同舟云学术

Clinical outcomes and cardiac safety of continuous antiHer2 therapy in c-erbB2-positive metastatic breast cancer patients

Published:2013-12 Issue:6 Volume:25 Page:369-375
ISSN:1120-009X
Container-title:Journal of Chemotherapy
language:en
Short-container-title:Journal of Chemotherapy

Author:

Fedele Palma,Orlando Laura,Schiavone Paola,Ciccarese Mariangela,Forcignanò Rosa Chiara,Calvani Nicola,Marino Antonella,Nacci Angelo,Sponziello Francesco,Mazzoni Enrica,Rizzo Pietro,Lorusso Vito,Cinieri Saverio

Publisher

Informa UK Limited

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Oncology

Link

http://www.tandfonline.com/doi/pdf/10.1080/10256018808623883

Reference50 articles.

1. Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases

2. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-A review

3. Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review

4. Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer

5. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Machine Learning–Based Risk Assessment for Cancer Therapy–Related Cardiac Dysfunction in 4300 Longitudinal Oncology Patients;Journal of the American Heart Association;2020-12

2. Temporal Trends of Cardiac Outcomes and Impact on Survival in Patients With Cancer;The American Journal of Cardiology;2020-12

3. Trastuzumab;Reactions Weekly;2014-03